First patient completes the TECVI-1 trial

The first patient of the TECVI-1 clinical trial successfully completed the 12-month follow-up for safety and efficacy. The first patient with Chronic Venous Insufficiency (CVI) had VERIGRAFT’s lead product, the Personalized Tissue Engineered Vein (P-TEV), implanted last year. During one year, no safety concerns were identified, the graft was patent and the valve was functional. P-TEV is an engineered human vein segment containing a functional venous valve that is implanted to replace a segment of a patient’s femoral vein carrying a defective valve.

The release as fetched from its publisher. verigraft.com ↗